These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 20931299)

  • 21. Randomized phase III trial of radiotherapy or chemoradiotherapy with topotecan and cisplatin in intermediate-risk cervical cancer patients after radical hysterectomy.
    Sun W; Wang T; Shi F; Wang J; Wang J; Hui B; Zhang Y; Lu J; Chen H; Liu Z
    BMC Cancer; 2015 May; 15():353. PubMed ID: 25935645
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydralazine and magnesium valproate as epigenetic treatment for myelodysplastic syndrome. Preliminary results of a phase-II trial.
    Candelaria M; Herrera A; Labardini J; González-Fierro A; Trejo-Becerril C; Taja-Chayeb L; Pérez-Cárdenas E; de la Cruz-Hernández E; Arias-Bofill D; Vidal S; Cervera E; Dueñas-Gonzalez A
    Ann Hematol; 2011 Apr; 90(4):379-87. PubMed ID: 20922525
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Pegfilgrastim in Patients Receiving First-Line FOLFOX/Bevacizumab or FOLFIRI/Bevacizumab for Locally Advanced or Metastatic Colorectal Cancer: Final Results of the Pegfilgrastim and Anti-VEGF Evaluation Study (PAVES).
    Pinter T; Klippel Z; Cesas A; Croitoru A; Decaestecker J; Gibbs P; Hotko Y; Jassem J; Kurteva G; Novotny J; O'Reilly S; Salek T; Reiner M; Morrow PK; Choi MR; Whittaker S; Blanke C
    Clin Colorectal Cancer; 2017 Jun; 16(2):103-114.e3. PubMed ID: 28038865
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Baselga J; Im SA; Iwata H; Cortés J; De Laurentiis M; Jiang Z; Arteaga CL; Jonat W; Clemons M; Ito Y; Awada A; Chia S; Jagiełło-Gruszfeld A; Pistilli B; Tseng LM; Hurvitz S; Masuda N; Takahashi M; Vuylsteke P; Hachemi S; Dharan B; Di Tomaso E; Urban P; Massacesi C; Campone M
    Lancet Oncol; 2017 Jul; 18(7):904-916. PubMed ID: 28576675
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L; de Marinis F; Dediu M; Thomas M; Pujol JL; Bidoli P; Molinier O; Sahoo TP; Laack E; Reck M; Corral J; Melemed S; John W; Chouaki N; Zimmermann AH; Visseren-Grul C; Gridelli C
    Lancet Oncol; 2012 Mar; 13(3):247-55. PubMed ID: 22341744
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.
    Ohtsu A; Shah MA; Van Cutsem E; Rha SY; Sawaki A; Park SR; Lim HY; Yamada Y; Wu J; Langer B; Starnawski M; Kang YK
    J Clin Oncol; 2011 Oct; 29(30):3968-76. PubMed ID: 21844504
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance).
    Baggstrom MQ; Socinski MA; Wang XF; Gu L; Stinchcombe TE; Edelman MJ; Baker S; Feliciano J; Novotny P; Hahn O; Crawford JA; Vokes EE
    J Thorac Oncol; 2017 May; 12(5):843-849. PubMed ID: 28161554
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial.
    Stehman FB; Ali S; Keys HM; Muderspach LI; Chafe WE; Gallup DG; Walker JL; Gersell D
    Am J Obstet Gynecol; 2007 Nov; 197(5):503.e1-6. PubMed ID: 17980189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab for advanced cervical cancer: patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240).
    Penson RT; Huang HQ; Wenzel LB; Monk BJ; Stockman S; Long HJ; Ramondetta LM; Landrum LM; Oaknin A; Reid TJ; Leitao MM; Method M; Michael H; Tewari KS
    Lancet Oncol; 2015 Mar; 16(3):301-11. PubMed ID: 25638326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II study of multimodality treatment for locally advanced cervical cancer: neoadjuvant carboplatin and paclitaxel followed by radical hysterectomy and adjuvant cisplatin chemoradiation.
    Dueñas-Gonzalez A; López-Graniel C; González-Enciso A; Cetina L; Rivera L; Mariscal I; Montalvo G; Gómez E; de la Garza J; Chanona G; Mohar A
    Ann Oncol; 2003 Aug; 14(8):1278-84. PubMed ID: 12881393
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized controlled trial comparing concurrent chemoradiation versus concurrent chemoradiation followed by adjuvant chemotherapy in locally advanced cervical cancer patients: ACTLACC trial.
    Tangjitgamol S; Tharavichitkul E; Tovanabutra C; Rongsriyam K; Asakij T; Paengchit K; Sukhaboon J; Penpattanagul S; Kridakara A; Hanprasertpong J; Chomprasert K; Wanglikitkoon S; Atjimakul T; Pariyawateekul P; Katanyoo K; Tanprasert P; Janweerachai W; Sangthawan D; Khunnarong J; Chottetanaprasith T; Supawattanabodee B; Lertsanguansinchai P; Srisomboon J; Isaranuwatchai W; Lorvidhaya V
    J Gynecol Oncol; 2019 Jul; 30(4):e82. PubMed ID: 31074236
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Analysis of prognostic factors and therapeutic patterns of recurrent stage Ⅰb-Ⅱa cervical squamous carcinoma treated with radical hysterectomy].
    Ou ZJ; Zhao D; An JS; Sun CY; Huang MN; Li B; Wu LY
    Zhonghua Fu Chan Ke Za Zhi; 2019 Jun; 54(6):399-405. PubMed ID: 31262124
    [No Abstract]   [Full Text] [Related]  

  • 33. Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
    Kim SB; Dent R; Im SA; Espié M; Blau S; Tan AR; Isakoff SJ; Oliveira M; Saura C; Wongchenko MJ; Kapp AV; Chan WY; Singel SM; Maslyar DJ; Baselga J;
    Lancet Oncol; 2017 Oct; 18(10):1360-1372. PubMed ID: 28800861
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study.
    Zanaboni F; Grijuela B; Giudici S; Cormio G; Babilonti L; Ghezzi F; Giorda G; Scambia G; Franchi M; Lorusso M; Ditto A; Lorusso D; Raspagliesi F
    Eur J Cancer; 2013 Mar; 49(5):1065-72. PubMed ID: 23151423
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tucidinostat plus exemestane for postmenopausal patients with advanced, hormone receptor-positive breast cancer (ACE): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Jiang Z; Li W; Hu X; Zhang Q; Sun T; Cui S; Wang S; Ouyang Q; Yin Y; Geng C; Tong Z; Cheng Y; Pan Y; Sun Y; Wang H; Ouyang T; Gu K; Feng J; Wang X; Wang S; Liu T; Gao J; Cristofanilli M; Ning Z; Lu X
    Lancet Oncol; 2019 Jun; 20(6):806-815. PubMed ID: 31036468
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure.
    Garcés-Eisele SJ; Cedillo-Carvallo B; Reyes-Núñez V; Estrada-Marín L; Vázquez-Pérez R; Juárez-Calderón M; Guzmán-García MO; Dueñas-González A; Ruiz-Argüelles A
    J Clin Pharm Ther; 2014 Aug; 39(4):368-75. PubMed ID: 24702251
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 2 trial of erlotinib combined with cisplatin and radiotherapy in patients with locally advanced cervical cancer.
    Nogueira-Rodrigues A; Moralez G; Grazziotin R; Carmo CC; Small IA; Alves FV; Mamede M; Erlich F; Viegas C; Triginelli SA; Ferreira CG
    Cancer; 2014 Apr; 120(8):1187-93. PubMed ID: 24615735
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial.
    Vergote I; Scambia G; O'Malley DM; Van Calster B; Park SY; Del Campo JM; Meier W; Bamias A; Colombo N; Wenham RM; Covens A; Marth C; Raza Mirza M; Kroep JR; Ma H; Pickett CA; Monk BJ;
    Lancet Oncol; 2019 Jun; 20(6):862-876. PubMed ID: 31076365
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Combined pretreatment with
    Ji S; Hu Q; Zhu J; Chen J; Chen Q; Liu Z; Shen C; Yang R; Sun H; Wu J; Gu K
    Trials; 2018 Aug; 19(1):416. PubMed ID: 30075736
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study.
    Gallion HH; Brunetto VL; Cibull M; Lentz SS; Reid G; Soper JT; Burger RA; Andersen W;
    J Clin Oncol; 2003 Oct; 21(20):3808-13. PubMed ID: 14551299
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.